Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes (Q38205581)

31 August 2017

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes (English)

1 reference

31 August 2017

0 references

1 reference

ChEBI release 2020-05-28

Elizabeth M Lamos

1

1 reference

31 August 2017

Lisa M Younk

series ordinal

2

1 reference

31 August 2017

Stephen N Davis

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

19 April 2014

1 reference

Expert Opinion on Investigational Drugs

31 August 2017

1 reference

31 August 2017

23

1 reference

31 August 2017

6

1 reference

31 August 2017

875-882

1 reference

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Hypoglycemia in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.909407

10.1517/13543784.2014.909407

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference